| 1.35 0.06 (4.65%) | 04-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2 | 1-year : | 2.31 |
| Resists | First : | 1.71 | Second : | 1.98 |
| Pivot price | 1.54  |
|||
| Supports | First : | 1.27 | Second : | 1.06 |
| MAs | MA(5) : | 1.34 |
MA(20) : | 1.59 |
| MA(100) : | 1.75 |
MA(250) : | 2.13 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.4 |
D(3) : | 5.6 |
| RSI | RSI(14): 32.1 |
|||
| 52-week | High : | 2.93 | Low : | 1.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NSPR ] has closed above bottom band by 20.0%. Bollinger Bands are 76.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.38 - 1.39 | 1.39 - 1.4 |
| Low: | 1.29 - 1.3 | 1.3 - 1.31 |
| Close: | 1.33 - 1.35 | 1.35 - 1.37 |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Fri, 10 Apr 2026
InspireMD (NSPR) asks shareholders to approve 150M→250M share increase - Stock Titan
Wed, 08 Apr 2026
After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR) - Yahoo Finance
Wed, 08 Apr 2026
InspireMD (NYSE:NSPR) Trading Down 6.7% - What's Next? - MarketBeat
Tue, 07 Apr 2026
After Dropping 15.2% Over the Past Four Weeks, This Is Why InspireMD (NSPR) Could See a Turnaround - Bitget
Fri, 03 Apr 2026
InspireMD Launches $75 Million At-The-Market Equity Program With BTIG - TradingView — Track All Markets
Fri, 03 Apr 2026
InspireMD (NSPR) launches up to $75M ATM program with BTIG as agent - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 42 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 20.7 (%) |
| Held by Institutions | 49.5 (%) |
| Shares Short | 20 (K) |
| Shares Short P.Month | 38 (K) |
| EPS | -0.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.26 |
| Profit Margin | 0 % |
| Operating Margin | -383.8 % |
| Return on Assets (ttm) | -53.4 % |
| Return on Equity (ttm) | -106.9 % |
| Qtrly Rev. Growth | 61.5 % |
| Gross Profit (p.s.) | 0.06 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -1.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -1.78 |
| PEG Ratio | 0 |
| Price to Book value | 1.06 |
| Price to Sales | 6.36 |
| Price to Cash Flow | -1.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|